DOCSLIB.ORG

February 2020 ACIP Meeting Minutes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
February 2020 ACIP Meeting Minutes DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 Atlanta, Georgia This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 Table of Contents Page Agenda 4-5 Acronyms 6-11 Wednesday: February 26, 2020 Welcome and Introductions 12-14 Ebola Vaccine Introduction Review of Ebola Virus Disease and rVSVΔG-ZEBOV-GP Vaccine GRADE 14-49 EtR and Summary of Work Group Considerations and Proposed Policy Options Vote 2019 Novel Coronavirus (2019-nCov) Informational Session 49-55 Influenza Vaccines Introduction Older Adult (65+) Adjuvanted Quadrivalent Influenza Vaccine (aIIV4) ‘ 2019-20 US Influenza Surveillance Update 56-72 2019-20 US Influenza Vaccine Effectiveness Update Safety of Adjuvanted vs. High-Dose Inactivated Influenza Vaccines in Older Adults Summary and Work Group Considerations Thursday: February 27, 2020 Agency Updates Centers for Disease Control and Prevention (CDC) Center for Medicare and Medicaid Services (CMS) Department of Defense (DoD) Department of Veteran’s Affairs (DVA) Food and Drug Administration (FDA) 73-77 Heath Resources and Services Administration (HRSA) Indian Health Services (I HS) National Institutes of Health (NIH) Office of Infectious Disease Policy and HIV/AIDS (OIDP) o National Vaccine Advisory Committee (NVAC) o National Vaccine Program Office (NVPO) Rabies Vaccine Introduction Background on PrEP, Vaccine Safety, and Work Group Considerations 78-96 Rabies Vaccine Schedule & Duration of Immunity (Systematic Review Data) Work Group Next Steps 2 This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 Dengue Virus Vaccines Introduction Dengue Vaccine Acceptability in Puerto Rico 96-111 SAGE Perspective on DENGVAXIA® Summary of Work Group Considerations Polio Informational Session Introduction 112-123 Polio and Polio Policy in the United States: The Oral Polio Vaccine to Inactivated Vaccine Switch Global Polio Eradication: Progress and Prospects Hepatitis B Vaccine 123-124 Work Group Updated General Best Practices Introduction 124-126 Update on Recent Postings Vaccine Supply 127 Certification 128 Membership Roster 129-137 3 This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 4 This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 5 This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 Acronyms AAFP American Academy of Family Physicians AAP American Academy of Pediatrics ACCV Advisory Commission on Childhood Vaccines ACHA American College Health Association ACIP Advisory Committee on Immunization Practices ACOG American College of Obstetricians and Gynecologists ACP American College of Physicians ACS American Cancer Society AE Adverse Event AECI Adverse Events of Clinical Interest AESI Adverse Events of Special Interest AFM Acute Flaccid Myelitis AFRO Africa Regional Office AHIP America’s Health Insurance Plans AI/AN American Indian/Alaskan Native aIIV Adjuvanted Inactivated Influenza Vaccine AIM Association of Immunization Managers AIRA American Immunization Registry Association AMA American Medical Association AMGA American Medical Group Association AOA American Osteopathic Association APhA American Pharmacists Association APHL Association of Public Health Laboratories AS American Samoa ASH Assistant Secretary for Health ASPR Assistant Secretary for Preparedness and Response ASTHO Association of State and Territorial Health Officers ATS American Thoracic Society BLA Biologics License Application BSC, DDID Board of Scientific Counselors, Deputy Director for Infectious Diseases BSL-4 Biosafety Level 4 CBER Center for Biologics Evaluation and Research ccIIV Cell Culture-Based Inactivated Influenza Vaccine CDC Centers for Disease Control and Prevention CEA Cost-Effectiveness Analysis CHMP Committee for Medicinal Products for Human Use CICP Countermeasures Injury Compensation Program CISA Clinical Immunization Safety Assessment CLD Chronic Liver Disease CLIA Clinical Laboratory Improvement Amendments CMS Center for Medicare and Medicaid Services CNS Central Nervous System COI Conflict of Interest COPA Communities Organized to Prevent Arboviruses COVID-19 Coronavirus Disease 2019 CSF Cerebrospinal Fluid CSTE Council of State and Territorial Epidemiologists 6 This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 cVDPV2 Circulating Vaccine-Derived Poliovirus DC District of Columbia DENV Dengue Virus DFO Designated Federal Official DNA Deoxyribonucleic Acid DoD Department of Defense DRC Democratic Republic of Congo DSMB Data Safety Monitoring Board DSTDP Division of STD Prevention DTaP Diphtheria and Tetanus Toxoid and Pertussis DVA Department of Veterans Affairs DVD Division of Viral Diseases ED Emergency Department EHR Electronic Health Record EIS Epidemic Intelligence Service ELISA Enzyme-Linked Immunosorbent Assay EMA European Medicines Agency EMP Essential Medicine Department EMR Electronic Medical Record EMRO Eastern Mediterranean Region Office EQ-5D-5L EuroQOL-5 Dimensions-5 Levels EQ-VAS EuroQol-Visual Analogue Scale ETC Ebola Treatment Center EtR Evidence to Recommendation EU European Union EUA Emergency Use Authorization EUL Emergency Use Listing EURO Europe Regional Office EV Enteroviruses EVD Ebola Virus Disease FDA Food and Drug Administration FQHC Federally Qualified Health Center FY Fiscal Year GAVI Global Alliance for Vaccines and Immunisation; The Vaccine Alliance GBS Guillain-Barré Syndrome GCC Global Certification Commission GCC (Tom Harkin) Global Communications Center GI Gastrointestinal GID Global Immunization Division GISRS Global Influenza Surveillance and Response System GMC Geometric Mean Concentration GMT Geometric Mean Titers GP Glycoprotein GPEI Global Polio Eradication Initiative GRADE Grading of Recommendation Assessment, Development and Evaluation GSK GlaxoSmithKline HAV Hepatitis A Virus HBIG Hepatitis B Immune Globulin HCoVs Human Coronaviruses 7 This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 HCP Healthcare Personnel / Providers HCW Healthcare Workers HDCV Human Diploid Cell Vaccine HD-IIV High-Dose Inactivated Influenza Vaccine HepA Hepatitis A HepB Hepatitis B HHS (Department of) Health and Human Services HI Hemagglutinin Inhibition HIV Human Immunodeficiency Virus HMO Health Maintenance Organization HPV Human Papillomavirus HRQOL Health-Related Quality of Life HRSA Health Resources and Services Administration ICD International Classification of Diseases IDCRP Infectious Disease Clinical Research Program ICU Intensive Care Unit ID Intradermal IDSA Infectious Disease Society of America Ig Immunoglobulin IHB Immunization Healthcare Branch IHD Immunization Healthcare Division (DoD) IHR International Health Regulation IHS Indian Health Service IIS Immunization Information Systems IIV Inactivated Influenza Vaccine ILI Influenza-Like Illness ILINet Influenza-like Illness Surveillance Network IM Intramuscular IPV Inactivated Polio Vaccine ISD Immunization Services Division ISO Immunization Safety Office ISTM International Society for Travel Medicine IVIG Intravenous Immunoglobulin KPSC Kaiser Permanent Southern California LAIV Live Attenuated Influenza Vaccine LRN Laboratory Response Network MASO Management Analysis and Services Office MedDRA Medical Dictionary for Regulatory Activities MERS Middle East Respiratory Syndrome MHS Military Health System MMR Measles, Mumps, and Rubella MMWR Morbidity and Mortality Weekly Report mOPV Monovalent OPV MSM Men Who Have Sex With Men MI Multiple Imputation NACCHO National Association of County and City Health Officials NACI National Advisory Committee on Immunization Canada NAIP National Adult Immunization Plan NAIIS National Adult and Influenza Immunization Summit 8 This document has been archived for historical purposes. (3/1/2020) https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2020-02-508.pdf Advisory Committee on Immunization Practices (ACIP) Summary Report February 26-27, 2020 NAM National Academy of Medicine NAP National Action Plan NAPNAP National Association of Pediatric Nurse Practitioners NAS National Academy of Sciences NCEZID National Center for Emerging and Zoonotic Infectious Diseases NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention NCHS
Load more

Recommended publications
  • Compendium of the Findings of the OPCAST Pandemic Subgroup 12
    1 A Compendium of the Findings of the Obama PCAST Ad Hoc Subgroup on Pandemic Preparedness and Response December 23, 2020 Introduction A subset of the former members of President Obama’s Council of Advisors on Science and Technology (here OPCAST)—ten individuals who played particularly important roles in producing the six OPCAST reports between 2009 and 2016 that dealt with issues related to pandemic preparedness and response1—came together starting in March of this year to consider how insights from those studies might be combined with more recent research and current observations to develop suggestions about how the U.S. response to the COVID-19 pandemic could be improved. The Subgroup has produced six reports, addressing • the national strategic pandemic-response stockpile (May 20) • the role of contact tracing (June 18) • the role of public health data in controlling the spread of COVID-19 (July 28) • testing for the pathogen (August 18) • recommendations for the coming COVID-19 commission (September 21) • needs for improved epidemiological modeling (September 28) Each report was distributed, upon completion, to selected members of the Trump COVID-19 team and the Biden campaign staff, selected governors and members of Congress, selected public health experts outside government, and the media. The reports have also been posted on the OPCAST team’s website, http://opcast.org, together with a few opinion pieces based on them. In the current volume, we have assembled all six reports in full, preceded by a set of brief summaries. Four of the reports are followed by short updates taking account of developments since the reports first came out.
    [Show full text]
  • MERS-Cov Data Sharing Case Study Report November 2018
    MERS-CoV Data Sharing Case Study Report November 2018 1. Introduction a. Background to the ongoing MERS-CoV outbreak: In September 2012, Dr Ali Mohamed Zaki reported the isolation of a novel betacoronavirus on ProMED-mail, the internet infectious disease alert system run by the International Society for Infectious Diseases.1 The patient, a 60-year-old male from Saudi Arabia presenting with pneumonia- like symptoms died from an unknown viral infection in June 2012.2 Later dubbed the Middle East Respiratory Syndrome Coronavirus (MERS-CoV),3 this emerging infectious disease has now been responsible for more than 2,200 laboratory-confirmed infections in people from 27 countries, and close to 800 deaths.4 The vast majority of these cases have been recorded in Saudi Arabia, however MERS-CoV is considered a severe emerging disease with the potential to cause a major global health emergency.5 Epidemiological investigations have revealed that primary human infections with MERS-CoV are often, but not always associated with contact with dromedary camels around the Arabian Peninsula.6 Human-to-human transmission of MERS-CoV has been responsible for case clusters in family groups and healthcare facilities. The incidence of hospital-acquired infections have been reduced with the employment of strict infection control measures,7 and the international public health community remain on high alert for new introductions. In 2015, South Korea saw the largest outbreak of MERS- CoV outside of the Eastern Mediterranean with 186 confirmed cases and 38 deaths.7 New cases of MERS-CoV infection continue to be reported mostly from the Eastern Mediterranean.
    [Show full text]
  • Alex Haslam Is a Social Psychologist and an Australian Laureate Fellow at the University of Queensland, Australia
    Alex Haslam is a social psychologist and an Australian Laureate Fellow at the University of Queensland, Australia. He is also a Senior Fellow of CIFAR’s Social Interactions, Identity & Well-Being program. His work examines how social identities and group memberships influence our interactions with others. He researches such questions as: How does belonging to groups and organizations shape the way we think, feel and behave? And how do individuals and groups in turn shape the nature of organizations and society? Dr. Haslam approaches these questions by identifying and explaining how people’s membership in groups and teams affects a range of social and organizational processes including stereotyping and prejudice, leadership and motivation, communication and decision-making, and stress and mental health. Dr Haslam is on the editorial board of seven international journals, including Scientific American Mind. He has published and edited 11 books on social and organizational psychology including the seminal book The Social Cure: Identity, Health and Well-being. His work has received numerous honours including the British Psychology Society's Award for Excellence in the Teaching of Psychology, and a National Teaching Fellowship from the Higher Education Academy. John Berry is a cross-cultural psychologist, and a member of CIFAR Advisory Board for the Social Interactions, Identity, & Well-being program. His research involves two domains. First is the examination of how individual behaviour is developed and displayed in different cultural contexts; much of the work has been with Indigenous Peoples in Canada, Africa and Asia. Second is research with immigrant and ethnocultural groups who are settled into plural societies in many parts of the world.
    [Show full text]
  • Recommendations for the Coming COVID-19 Commission
    Recommendations for the Coming COVID-19 Commission By a Pandemic-Response Subgroup of Former Members of President Obama’s Council of Advisors on Science and Technology September 21, 2020 Introduction The United States confronted a succession of biological threats over the first two decades of the twenty-first century. These included the 2001 anthrax attacks, the 2002-2004 SARS coronavirus (SARS-CoV-1) pandemic, the 2009 H1N1 influenza pandemic, the 2012 MERS-CoV coronavirus epidemic in the Mideast, the 2014 Ebola outbreak in Africa, and the 2015-2016 mosquito-borne Zika virus epidemic in the Americas. This pace of emerging disease outbreaks had been anticipated by leading microbiologists and epidemiologists in the late twentieth century.1 In 2004, the National Intelligence Council in its report Mapping the Global Future, noted that “Some experts believe it is only a matter of time before a new pandemic appears, such as the 1918–1919 influenza virus ... Such a pandemic… would be devastating and could spread rapidly throughout the world.”2 In 2008, a careful accounting catalogued the emergence of 335 infectious diseases into humans between 1940 and 2004.3 While a small number of these spread widely or even became established (for example, the HIV virus that causes AIDS), nearly all subsided quickly. But it was clear to microbiologists that the threat was ever-present, and likely increasing. The executive branch first put a national strategy in place for pandemic disease outbreak surveillance and response with Presidential Decision Directive PDD NSTC-7, issued by President Clinton in 1996.4 Since then there has been a series of U.S.
    [Show full text]
  • @Risk: the Last COVID Mile with Helen Branswell [Music] Jodi: Hey, I’M Jodi Butts
    @Risk: The Last COVID Mile with Helen Branswell [Music] Jodi: Hey, I’m Jodi Butts. And welcome to @Risk, brought to you by Interac. It's been a long risky year in large part due to COVID-19 and its sprawling health and economic consequences. Thanks to the development of effective vaccines, we can finally see some light at the end of the pandemic tunnel. Let's be buoyed by this over the holidays, but not get too ahead of ourselves either. What about this last mile of our COVID-19 journey? What are the potential bottlenecks and stumbling points that we should be looking out for? What should we be considering to ensure we reach our zero COVID-19 destination? To explore these questions I’m joined by Helen Branswell. Helen is Stat News's infectious diseases and global health reporter. She's Canadian and was introduced to epidemic reporting during Toronto's SARS outbreak in 2003. In the years since, she has written about bird flu, the H1N1 flu pandemic, Ebola, Zika, and now leads stats coverage of the coronavirus pandemic. Helen spent the summer of 2004 embedded at the US Centers for Disease Control and Prevention as a CDC knight fellow. In 2010 and 2011, she was a Neiman global health fellow at Harvard where she focused on polio eradication. Nobody covers the COVID-19 vaccine beat more thoughtfully or with more rigor than Helen. Our journey to this point has been long. Let's not stumble now with the end in sight. Lucky for us, Helen Branswell has us covered.
    [Show full text]
  • Global Vaccination: Trends and U.S
    Global Vaccination: Trends and U.S. Role October 18, 2019 Congressional Research Service https://crsreports.congress.gov R45975 SUMMARY R45975 Global Vaccination: Trends and U.S. Role October 18, 2019 For more than 50 years, the United States has taken an interest in the eradication of vaccine- preventable diseases (VPDs) in children worldwide, as well as vaccine research and Sara M. Tharakan development, particularly since playing a vital role in the global campaign to eradicate smallpox Analyst in Global Health in the 1960s. Since then, vaccinating children against VPDs has been a major U.S. foreign policy and International effort. Development Vaccinations are one of the most cost-effective ways to prevent infectious disease and associated morbidity and mortality. According to UNICEF, immunizations save around 3 million lives per year. As of 2019, VPDs continue to cause high levels of morbidity (illness) and mortality (death), and the World Health Organization (WHO) notes that the adoption of new vaccines by low- and middle-income countries (which often have the highest disease burdens) has been slower than in high-income countries. Receiving a vaccination during childhood can protect the recipient from VPDs, decrease the spread of related diseases, and improve child survival prospects (as children, particularly those under five years old, are more likely than adults to die from VPDs). Recently, a global resurgence of certain VPDs has caused concern among public health officials and drawn attention to the challenges of vaccine hesitancy and stigma. For example, polio continues to elude global eradication and remains endemic in three countries. In 2019 measles has seen a resurgence in some middle- and high-income countries due to a variety of factors, including reluctance among some individuals and religious communities to vaccinate their children.
    [Show full text]
  • Improving Pandemic Preparedness: Lessons from COVID-19
    Independent Task Force Report No. 78 Improving Pandemic Preparedness Lessons From COVID-19 Sylvia Mathews Burwell and Frances Fragos Townsend, Chairs Thomas J. Bollyky and Stewart M. Patrick, Project Directors Independent Task Force Report No. 78 Improving Pandemic Preparedness Lessons From COVID-19 Sylvia Mathews Burwell and Frances Fragos Townsend, Chairs Thomas J. Bollyky and Stewart M. Patrick, Project Directors The Council on Foreign Relations (CFR) is an independent, nonpartisan membership organization, think tank, and publisher dedicated to being a resource for its members, government officials, business executives, journalists, educators and students, civic and religious leaders, and other interested citizens in order to help them better understand the world and the foreign policy choices facing the United States and other countries. Founded in 1921, CFR carries out its mission by maintaining a diverse membership, with special programs to promote interest and develop expertise in the next generation of foreign policy leaders; convening meetings at its headquarters in New York and in Washington, DC, and other cities where senior government officials, members of Congress, global leaders, and prominent thinkers come together with Council members to discuss and debate major international issues; supporting a Studies Program that fosters independent research, enabling CFR scholars to produce articles, reports, and books and hold roundtables that analyze foreign policy issues and make concrete policy recommendations; publishing Foreign Affairs, the preeminent journal on international affairs and U.S. foreign policy; sponsoring Independent Task Forces that produce reports with both findings and policy prescriptions on the most important foreign policy topics; and providing up-to- date information and analysis about world events and American foreign policy on its website, CFR.org.
    [Show full text]
  • California, the Model State Emergency Health Powers Act, and Protecting Civil Liberties During a Public Health Emergency
    California Western Law Review Volume 42 Number 2 Article 4 2006 Bioterrorism or Avian Influenza: California, The Model State Emergency Health Powers Act, and Protecting Civil Liberties During a Public Health Emergency N. Pieter M. O'Leary Follow this and additional works at: https://scholarlycommons.law.cwsl.edu/cwlr Recommended Citation O'Leary, N. Pieter M. (2006) "Bioterrorism or Avian Influenza: California, The Model State Emergency Health Powers Act, and Protecting Civil Liberties During a Public Health Emergency," California Western Law Review: Vol. 42 : No. 2 , Article 4. Available at: https://scholarlycommons.law.cwsl.edu/cwlr/vol42/iss2/4 This Article is brought to you for free and open access by CWSL Scholarly Commons. It has been accepted for inclusion in California Western Law Review by an authorized editor of CWSL Scholarly Commons. For more information, please contact [email protected]. O'Leary: Bioterrorism or Avian Influenza: California, The Model State Emer BIOTERRORISM OR AVIAN INFLUENZA: CALIFORNIA, THE MODEL STATE EMERGENCY HEALTH POWERS ACT, AND PROTECTING CIVIL LIBERTIES DURING A PUBLIC HEALTH EMERGENCY N. PIETER M. O'LEARY* I. INTRODUCTION The terrorist attacks of September 11, 2001 brought home for many people the need for increased national security.1 The world be- came a different place after the end of the Cold War; the new enemies to the American way of life were radical ideologues, religious zealots, and homegrown ultra-patriots.2 The nation's safety and stability had to be protected against future attacks from any of these groups and from the various means with which they chose to attack the American government and people.3 Even before the tragic attacks of September 11, 2001, the United States had been preparing for the eventualities of a devastating terror- ist attack upon the country.4 After all, terror attacks come in many * J.D., California Western School of Law; M.A.
    [Show full text]
  • Cock-A-Doodle-Doo: Pandemic Avian Influenza and the Legal Preparation and Consequences of an H5N1 Influenza Outbreak N
    Health Matrix: The Journal of Law- Medicine Volume 16 | Issue 2 2006 Cock-a-Doodle-Doo: Pandemic Avian Influenza and the Legal Preparation and Consequences of an H5N1 Influenza Outbreak N. Pieter M. O'Leary Follow this and additional works at: https://scholarlycommons.law.case.edu/healthmatrix Part of the Health Law and Policy Commons Recommended Citation N. Pieter M. O'Leary, Cock-a-Doodle-Doo: Pandemic Avian Influenza and the Legal Preparation and Consequences of an H5N1 Influenza Outbreak, 16 Health Matrix 511 (2006) Available at: https://scholarlycommons.law.case.edu/healthmatrix/vol16/iss2/7 This Article is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It has been accepted for inclusion in Health Matrix: The ourJ nal of Law-Medicine by an authorized administrator of Case Western Reserve University School of Law Scholarly Commons. COCK-A-DOODLE-DOO: PANDEMIC AVIAN INFLUENZA AND THE LEGAL PREPARATION AND CONSEQUENCES OF AN H5N 1 INFLUENZA OUTBREAK N. PieterM 0 'Learyt INTRODUCTION Epidemic disease has long played a role in the evolution of man- kind. As mankind evolved, disease impacted his laws. With disease outbreak came chaos, death, and change. As we learned to recognize the causes of disease, laws attempted to prevent and combat the threat.' The combat continues today in our global challenge to halt the spread of devastating diseases like HIV/AIDS. The greatest pending threat modem man faces from infectious disease, however, is not a slow moving disease like HIV/AIDS,2 but a fast moving and virulent influenza outbreak on par with the 1918 pan- demic.3 Such an outbreak would threaten the political, social, and legal fabric holding modem society together.
    [Show full text]
  • Is Global Capacity to Manage Outbreaks Improving?: an Analysis
    IS GLOBAL CAPACITY TO MANAGE OUTBREAKS IMPROVING?: AN ANALYSIS GLOBAL HEALTH CENTRE WORKING PAPER NO.17 | 2018 IS GLOBAL CAPACITY TO MANAGE OUTBREAKS IMPROVING? - AN ANALYSIS Jennifer Leigh, Suerie Moon, Elvis Garcia, Gabrielle Fitzgerald | 1 GLOBAL HEALTH CENTRE WORKING PAPER NO. 17 | 2018 GLOBAL HEALTH CENTRE WORKING PAPER NO. 17 | 2018 Global Health Centre Graduate Institute of International and Development Studies Chemin Eugène-Rigot 2 | Case Postale 1672 1211 Geneva 21 – Switzerland Tel + 41 22 908 4558 Fax + 41 22 908 4594 Email [email protected] graduateinstitute.ch/globalhealth 2 | IS GLOBAL CAPACITY TO MANAGE OUTBREAKS IMPROVING?: AN ANALYSIS CONTENTS Abbreviations . 4 Acknowledgements . 5 Executive Summary . 7 Introduction . 11 Leadership & monitoring . 13 Financing . 15 National health systems capacity. 18 Table 1: Status of Joint External Evaluations . 18 Panel 1: Building outbreak management capacity in Liberia . 23 World Health Organization. 24 The humanitarian aid system . 25 Research and development of health technologies. 27 Knowledge (data) sharing . 30 Travel and trade restrictions. 34 Conclusions . 35 Endnotes. 36 | 3 GLOBAL HEALTH CENTRE WORKING PAPER NO. 17 | 2018 ABBREVIATIONS Africa CDC Africa Centers for Disease Control IDA International Development Association CDC US Centers for Disease Control and IDDO Infectious Diseases Data Observatory Prevention IHR International Health Regulations (2005) CEPI Coalition for Epidemic Preparedness IMF International Monetary Fund Innovations JEE Joint External
    [Show full text]
  • The COVID-19 Vaccine Race: Intellectual Property, Collaboration(S), Nationalism and Misinformation
    Washington University Journal of Law & Policy Volume 64 The Legal Impacts of COVID-19 2021 The COVID-19 Vaccine Race: Intellectual Property, Collaboration(s), Nationalism and Misinformation Ana Santos Rutschman Saint Louis University School of Law Follow this and additional works at: https://openscholarship.wustl.edu/law_journal_law_policy Part of the Food and Drug Law Commons, Health Law and Policy Commons, Intellectual Property Law Commons, Pharmaceutics and Drug Design Commons, Public Health Education and Promotion Commons, Science and Technology Law Commons, and the Virus Diseases Commons Recommended Citation Ana Santos Rutschman, The COVID-19 Vaccine Race: Intellectual Property, Collaboration(s), Nationalism and Misinformation, 64 WASH. U. J. L. & POL’Y 167 (2021), https://openscholarship.wustl.edu/law_journal_law_policy/vol64/iss1/12 This Article is brought to you for free and open access by the Law School at Washington University Open Scholarship. It has been accepted for inclusion in Washington University Journal of Law & Policy by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. THE COVID-19 VACCINE RACE: INTELLECTUAL PROPERTY, COLLABORATION(S), NATIONALISM AND MISINFORMATION Ana Santos Rutschman* ABSTRACT The COVID-19 pandemic has brought a national and global vaccine race. This Article examines the race with respect to contemporary frameworks for biopharmaceutical research and development. Specifically, this Article focuses on the effect of patents, pre-production agreements, public-private partnerships, and vaccine misinformation. This Article analyzes lessons learned from the COVID-19 pandemic, advocates for promoting vaccine affordability and equity, and suggests modifications to existing preparedness frameworks to prepare for upcoming outbreaks of infectious disease.
    [Show full text]
  • Anticipating Pandemic Avian Influenza: Why the Ederf Al and State Preparedness Plans Are for the Birds
    DePaul Journal of Health Care Law Volume 10 Issue 2 Winter 2007: Symposium - Shaping a New Direction for Law and Medicine: An Article 4 International Debate on Culture, Disaster, Biotechnology and Public Health October 2015 Anticipating Pandemic Avian Influenza: Why the ederF al and State Preparedness Plans Are for the Birds Hillary R. Ahle Follow this and additional works at: https://via.library.depaul.edu/jhcl Recommended Citation Hillary R. Ahle, Anticipating Pandemic Avian Influenza: Why the ederF al and State Preparedness Plans Are for the Birds, 10 DePaul J. Health Care L. 213 (2007) Available at: https://via.library.depaul.edu/jhcl/vol10/iss2/4 This Article is brought to you for free and open access by the College of Law at Via Sapientiae. It has been accepted for inclusion in DePaul Journal of Health Care Law by an authorized editor of Via Sapientiae. For more information, please contact [email protected]. ANTICIPATING PANDEMIC AVIAN INFLUENZA: WHY THE FEDERAL AND STATE PREPAREDNESS PLANS ARE FOR THE BIRDS I Hillary R. Ahle The (1918 Spanish Influenza) epidemic killed, at a very, very conservative estimate.. .550,000 Americans in ten months, that's more Americans than died in combat in all the wars of this century... the epidemic killed at least 30 million in the world and infected the majority of the human species... As soon as the dying stopped, the forgetting began.2 The pandemic clock is ticking, we just don't know what time it is.3 I. INTRODUCTION Remember the last time you woke up on a winter morning with a sore throat, fever, and chills? You likely turned off your alarm, called into work sick, crawled back under the covers, and braced yourself to endure the obvious culprit, the flu.
    [Show full text]